BioAgilytix Closes Acquisition of Australia-based 360biolabs (R)
PR92315
DURHAM, N.C., Oct. 14, 2021 /PRNewswire=KYODO JBN/ --
-- Following final government approval, 360biolabs, a BioAgilytix company, adds
world-class virology & immunology expertise and LC/MS/MS small molecule
capabilities to the company, enabling support of bioanalytical services across
all geographies and development stages
BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research
organization focused on supporting pharmaceutical and biotech partners in all
phases of drug development, announced today that, following Australian Foreign
Investment Review Board ("FIRB") approval, it officially closed the purchase of
360biolabs(R). The acquisition of the company, now known as 360biolabs, a
BioAgilytix company, expands BioAgilytix's capabilities into first-in-human
trials (FIH), early-phase clinical trials and adds additional capacity by
joining 360biolabs' internationally recognized quality systems in Melbourne and
Brisbane with its existing laboratories in Durham, North Carolina; Boston,
Massachusetts; San Diego, California and Hamburg, Germany.
Logo -
https://mma.prnewswire.com/media/1659727/360biolabs_logo_RGB_tagline_Logo.jpg
Located in Australia's biomedical and clinical research hubs, Victoria and
Queensland, 360biolabs offers world-class virology and immunology expertise,
with BSL 2 and 3 laboratories, biomarker and immune monitoring capabilities
with a state-of-the-art flow cytometry suite, molecular biology PCR suite and
expansive bioanalytical LC/MS/MS small molecule capabilities.
"We are delighted to announce the final close of the 360biolabs acquisition, as
it's such positive and exciting news for our global team and customers. Our
expanded capacity, expertise and agility to now serve clients across all
geographies is unprecedented," said Jim Datin, President and CEO of
BioAgilytix. "360biolabs' leadership position in virology and immunology, plus
their small molecule capabilities and locations in Melbourne and Brisbane, help
make BioAgilytix an end-to-end bioanalytical force dedicated to helping
generate new innovations and life-changing therapeutics for patients around the
world."
"Our team is thrilled to formally join forces with BioAgilytix, as we already
share so much culturally, from our mutual strong scientific track record to our
commitment to quality science enabling innovative medicines to be developed for
patients. Together we will provide an exceptional range of specialized assays
and services to fulfill our clients' high expectations on a global scale," said
Alistair Draffan, CEO of 360biolabs. "We have no doubt that the combined group
is more than up to the task of tackling the world's many health challenges,
whether the pandemic or treatments for unmet clinical needs."
BioAgilytix selected White & Case as legal counsel to oversee the closing of
the acquisition, with Lazards Australia and Allens representing 360biolabs.
About BioAgilytix
BioAgilytix is a leading global contract research organization focused on
supporting pharmaceutical and biotech partners in all phases of drug
development. With laboratory locations in North Carolina's Research Triangle
Park; Cambridge, Massachusetts; San Diego, California; Melbourne and Brisbane,
Australia and Hamburg, Germany, BioAgilytix provides PK, immunogenicity,
biomarkers, and cell-based assay services supporting the development and
release testing of therapeutics across a number of industries and disease
states.
BioAgilytix offers assay development, validation, and sample analysis under
non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e., product
release testing, stability testing, etc.) BioAgilytix also offers diagnostic
testing services at its CLIA-certified, CAP-accredited Boston laboratory.
BioAgilytix's team of highly experienced scientific and QA professionals
ensures high-quality science, data integrity and regulatory compliance through
all phases of clinical development. BioAgilytix is a trusted partner to many
top global pharmaceutical and biotech companies. For more information, visit
www.bioagilytix.com.
About 360biolabs(R), a BioAgilytix company 360biolabs(R), a BioAgilytix
company, is the leading and most comprehensive specialty laboratory in the
Australia and New Zealand region. Our expert pharmacokinetic (PK) and
pharmacodynamic (PD) assay services support small molecule, biologic, vaccine
and other innovative therapeutic solutions to human health. A world class and
industry experienced technical team, known for their ability to successfully
deliver technically challenging assays, 360biolabs® supports global
pharmaceutical and biotech companies in a diverse and growing range of
therapeutics areas.
360biolabs(R) delivers global regulatory compliant assays and reports following
ISO/IEC 17025, ISO 15189, OECD GLP, GCLP and ICH GCP with a focus on quality.
For more information, visit www.360biolabs.com.
Media Contact:
Pam O'Connor
BioAgilytix
+1 919-621-1230
pam.oconnor@bioagilytix.com
SOURCE: BioAgilytix
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。